The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.

Switzerland's DINAMIQS receives Swissmedic approval for GMP viral vector production, becoming the country's first fully ...

ReiThera, based in Rome Italy, received operational authorization from the Italian Medicines Agency (AIFA) to open a production area at its pharmaceutical facility at the Castel Romano Technopole for ...

Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...

Efficient viral vector production is essential for the cost-effective manufacture of cell and gene therapies. Many of the current production workflows are reliant on basal media in batch-mode, which ...

Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...

Asimov’s LV Edge Packaging cell line routinely achieves high titers for therapeutic transgenes and is now available at AGC Biologics’ Cell and Gene Center of Excellence Asimov, the synthetic biology ...

LONDON, March 9, 2026 /PRNewswire/ -- The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence ...